TY  - GEN
AU  - Wohl,D A
AU  - Bhatti,L
AU  - Small,C B
AU  - Edelstein,H
AU  - Zhao,H H
AU  - Margolis,D A
AU  - DeJesus,E
AU  - Weinberg,W G
AU  - Ross,L L
AU  - Shaefer,M S
TI  - The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir
SN  - 1468-1293
PY  - 2016///1213
KW  - Adult
KW  - Anti-HIV Agents
KW  - therapeutic use
KW  - Antiretroviral Therapy, Highly Active
KW  - Atazanavir Sulfate
KW  - Biomarkers
KW  - blood
KW  - Bone Density
KW  - drug effects
KW  - CD4 Lymphocyte Count
KW  - Dideoxynucleosides
KW  - Drug Combinations
KW  - Drug Substitution
KW  - methods
KW  - Female
KW  - HIV Infections
KW  - Humans
KW  - Kidney
KW  - Lamivudine
KW  - Lipids
KW  - Male
KW  - Middle Aged
KW  - RNA, Viral
KW  - Ritonavir
KW  - adverse effects
KW  - Treatment Outcome
KW  - Viral Load
N1  - Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/hiv.12281
ER  -